Agoracom Blog Home

Posts Tagged ‘Stillcanna’

Newer Entries »

Mota Ventures $MOTA.ca Announces Successful Launch of New “Immune Support” Product $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-JC at 5:23 PM on Wednesday, March 18th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/Mota-Square-Logo-For-Blog.jpg
  • First Class CBD has launched a new “immune support” product that has generated significant demand since it was released
  • This is the first of a number of new CBD products aimed at promoting personal immune health that First Class is developing
  • During the first four days, company acquired over 1,000 customers and will be scaling rapidly

VANCOUVER, BC / March 18, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) announces that First Class CBD has launched a new “immune support” product that has generated significant demand since it was released. This is the first of a number of new CBD products aimed at promoting personal immune health that First Class is developing.

One of our primary competitive advantages as a business is our ability to adapt to market changes. With the immense demand in the market for products to promote personal immune system health, we launched a First Class immune product; during the first four days, we acquired over 1,000 customers and will be scaling rapidly. Next week we will be launching a complete line of immunity products, including a CBD oil plus B-vitamins, Vitamin C and Zinc.

Our mission is to provide pure and efficacious products to our customers that depend upon us throughout the United States and Europe. Our supply chain is functioning uninterrupted. The Company has personally met with suppliers in the United States and are confident in its ability to continue to meet the demands of the current sales volume, and new product lines for March 2020 and beyond.

“I am extremely pleased with the success of our launch of our new product line. Our ability to adapt and innovate is stronger than ever. Demand for our new immune category has been exceptional and I believe this will be a significant driver to revenue in 2020,” stated Ryan Hoggan, CEO of the Company.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact the President of the Company, Joel Shacker, at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the business prospects of First Class CBD and its new product lines, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Mota Ventures Corp.

Tags: , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Announces Successful Launch of New “Immune Support” Product $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Schedules Conference Call $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 4:10 AM on Tuesday, March 17th, 2020

VANCOUVER, BC, CANADA (MARCH 17, 2020) – MOTA VENTURES CORP. (CSE: MOTA FSE: 1WZ: GR OTC: PEMTF) (the “Company”or “Mota Ventures”) an emerging direct to consumer global CBD brand, is pleased to announce it will be hosting an investor conference call on Wednesday, March 18, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss current developments

The call will be held on Wednesday, March 18th, at 1:15 pm Pacific Time.  Media are invited to attend on a listen-only basis.

Conference details:

Canada/USA TF: 1-800-319-4610

International Toll: +1-604-638-5340

Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413

International Toll: +1-604-638-9010

Replay Access Code: 4251

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year round growing conditions and access to all necessary infrastructure. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Joel Shacker

President

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Schedules Conference Call $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:33 PM on Friday, March 13th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg

VANCOUVER, BC / March 13, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) is excited to announce that for the month of February 2020, its First Class CBD brand achieved sales of Cdn$2,981,000, with related expenses for the same time period totaling Cdn$2,814,000. Due to accelerated marketing efforts in late January 2020, the brand was able to improve gross margins by 4.9% from January 2020 to February 2020. The Company anticipates these efforts will yield a further positive impact on revenue and margin in subsequent months. Sales for February 2019 were Cdn$320,000; therefore, February 2020 represents an increase of 832% over the same period last year.

First Class offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. The Company plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of the First Class brand through the beginning months of 2020. The continued growth we are experiencing is evidence of the strong consumer demand in the CBD market. While eCommerce demand is generally weakest in January and February, we continue to demonstrate our leadership through achieving approximately Cdn$5,874,000 in revenue through the first two months of the year,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollar into Canadian dollar using the Bank of Canada monthly average exchange rates of 1.3301 for January 2019, 1.3206 for February 2019, 1.3087 for January 2020 and 1.3286 for February 2020.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Tags: , , , , , , , , , , ,
Posted in All Recent Posts | Comments Off on Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:00 PM on Thursday, March 12th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • These countries are expected to account for virtually all of the legal marijuana sold globally in five years

Marijuana is one of the fastest growing industries on the planet. Legal weed sales have more than tripled between 2014 and 2018, and they’re on track to roughly quadruple between the $10.9 billion generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales by 2024. That’s according to the 2019 “State of the Legal Cannabis Markets” report released earlier this year by Arcview Market Research and BDS Analytics.

Yet, what you might find intriguing about this rapid growth is that it’ll wind up being attributed to just a select few countries. Even though more than three dozen countries around the world have legalized medical marijuana, five countries are forecast by Arcview and BDS to account for $38.2 billion of this aforementioned $40.6 billion in licensed-store sales by 2024. Note, licensed-store sales doesn’t include general retailers selling cannabidiol (CBD) products, or cannabinoid-based drug developers selling pot-derived pharmaceuticals.

1. United States: $30.1 billion in cannabis spending by 2024

As should be no surprise, the U.S. projects as the leading marijuana market in the world by sales in 2024. In fact, the $30.1 billion in licensed-store revenue should comprise almost three-quarters of global licensed sales. According to Arcview and BDS, $9 billion of these sales are expected to come from the medical side of the equation, up from $4 billion in 2018, with the remaining $21.1 billion derived from recreational marijuana, up from $5.9 billion last year.

The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesn’t change its classification of marijuana from Schedule I. As long as Congress and the president continue to respect the right of states to make their own choices on cannabis, the industry could have plenty of runway.

One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF). Cresco, which holds the licenses to more than four dozen retail locations in 11 states, made a bold move in April when it announced an all-stock deal to acquire Origin House (OTC:ORHOF). Origin House is one of only a few companies to hold a cannabis distribution license in California, the state responsible for a quarter of all U.S. marijuana spending by 2024. Thus, Cresco Labs’ purchase of Origin House will give it access to more than 500 Californian dispensaries, and over 700 nationwide. Cresco and its vertically integrated peers appear well-positioned to take advantage of this huge growth opportunity.

2. Canada: $5.18 billion by 2024

Despite being the first industrialized country in the world to legalize recreational weed, Canada looks to take a distant second to the United States by 2024 in terms of sales. Arcview and BDS are projecting that $4.8 billion in sales will come from the recreational market by then, with the remainder made up of medical cannabis sales. It’s not uncommon for the medical industry to get cannibalized when adult-use marijuana is legalized, because it means patients no longer have to wait for a doctor’s approval and prescription to buy weed.

There’s a lot of competition in Canada right now, so it’s still unclear which company will be Canada’s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential. Aurora is already leaps and bounds ahead of its next-closest competitors with an annual run-rate output of 150,000 kilos as of the end of March, and plans to be producing at least 625,000 kilos on a run-rate basis by the end of June 2020. With most of this production located in Canada, and the company sporting a number of large-scale grow farms, Aurora Cannabis should be able to take advantage of economies of scale to drive down its growing costs per gram.

Of course, the real near-term excitement revolves around the upcoming launch of derivative products (e.g,, edibles, vapes, topicals, concentrates, and infused beverages) by mid-December. Derivatives have much better margins and pricing power than dried cannabis flower, which is why Aurora Cannabis and its peers have been busy beefing up their product offerings over the past year in preparation for this upcoming launch date.

3. Germany: $1.35 billion by 2024

Even though Arcview and BDS are not expecting Germany to legalize recreational cannabis, the company’s highly permissive stance toward medical marijuana, and the fact that health insurers cover medical weed in the country, should allow sales to soar from $79 million in 2018 to $1.35 billion by 2024.

Interestingly enough, Canadian cannabis stocks were actually big-time winners of the German cultivation licensing process. Both Aurora Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany. For its part, Aphria plans to have an 8,000-square-meter facility in Germany that’ll begin supplying the country with medical marijuana in the early part of 2020. In addition to growing cannabis, Aphria introduced CannRelief in Germany, which is a CBD-based nutraceutical and cosmetics product line. 

As for Aurora Cannabis, its approval to construct a growing facility will allow the company to supply the German market with 4,000 kilos of marijuana over four years, with shipments expected to commence October 2020. Of course, this production capacity is liable to be bumped up if patient demand merits it. 

4. Mexico: $1.02 billion by 2024

Arguably one of the oddest “legality” situations concerning marijuana right now is with Mexico. The nation’s Supreme Court has ruled five times since 2015 that imposing a ban on recreational cannabis is unconstitutional. That’s important, because when Mexico’s Supreme Court reaches five similar decisions on an issue, it becomes the standard throughout the country. Or, in layman’s terms, the Supreme Court has essentially affirmed the legality of recreational marijuana and is simply waiting for lawmakers in the country to hash out the details.

According to Arcview and BDS, Mexico will have legalized adult-use cannabis by 2024, although the ramp-up of legal sales could be slow. By 2024, recreational weed sales are only expected total $582 million, with an additional $441 million in medical spending, for a combined $1.02 billion. Mexico’s considerably larger population than Canada makes for an attractive market opportunity, but it’s unclear how well legal industries will fare with the noted presence of illicit producers.

One company that hasn’t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils into Mexico in 2016, giving it a head start on building important relationships with the country’s medical community. You’ll note that even with recreational legalization likely on the horizon, medical spending should continue to grow in Mexico. That gives Medical Marijuana and its RSHO-X hemp oil a real shot to continue penetrating the Mexico’s medical cannabis market. 

5. United Kingdom: $546.9 million by 2024

Although it may not be on track to tip the scales at $1 billion in sales by 2024, the U.K. is poised to be one of the fastest growing countries in the world based on cannabis spending. After only $9.9 million in medical spending last year, Britain is forecast for almost $547 million in medical marijuana revenue by 2024, representing a compound annual growth rate of 95.2%.

This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year. GW Pharmaceuticals’ CBD-based oral solution known as Epidiolex dazzled in late-stage studies and wound up reducing seizure frequency for patients with two rare forms of childhood-onset epilepsy by 30% to 40%. Additionally, GW Pharmaceuticals’ Sativex, an oromucosal spray containing both CBD and tetrahydrocannabinol (THC), is approved in more than a dozen markets in Europe (but not the U.S.).

Britain’s citizens and its government have seen what the U.K.-based GW Pharmaceuticals can do with cannabinoids, and its government has been open to the possibility of expanding access to marijuana-based products for medical patients.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.

SOURCE: https://www.fool.com/investing/2019/09/08/5-countries-with-the-highest-cannabis-spending-by.aspx

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on 2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

CLIENT FEATURE: Mota Ventures MOTA.ca – $29,000,000 in Combined Sales with 2019 EBITDA of Approximately 12.5% $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:53 PM on Wednesday, March 11th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

MOTA:CSE

RECENT HIGHLIGHTS

  • Direct to Consumer E-commerce retailer
  • Revenue generating, EBIDTA positive
  • Formalized Joint Venture With Bevcanna Enterprises: Read More
    • Will share equal ownership in the Joint Venture and will be jointly responsible for developing and funding its operations
    • Company will provide manufacturing, marketing and distribution infrastructure in the European market.
    • Parties have determined an initial product launch and will provide further details on specific regions and timing once finalize
  • Announced Collaboration for Sativida US Expansion Read More 
    • Unified Funding will provide assistance to Sativida with product sourcing, packaging, shipping, payment infrastructure and marketing
    • Sativida has become the number one search-ranked online retailer of CBD products in Spain and Mexico
  • Entered into Licensing Agreement with Phenome One Read More
    • A privately held full-service live genetic and seed preservation cannabis company.
    • Mota will have full access to Canada’s largest live genetic cannabis library with over 350 cultivars
    • Mota will have the right to propagate, cultivate, harvest and process a minimum of 10 selected cultivars

2 World Class Brands

#1. FIRST CLASS CBD

ONE OF THE LARGEST US BASED ONLINE RETAILERS OF CBD PRODUCTS

HIGHLIGHTS:

  • Leader in online CBD sales in North America
  • Crop to package model: US grown CBD hemp
  • Acquired at a 1.5 times revenue valuation
  • Current customer base 142,000 customers -with additional leads of over 424,000 potential new customers
  • 2019 Sales of $19.2M USD/ EBITDA of 2.7M USD

  #2. SATIVIDA

ONLINE DIRECT TO CONSUMER RETAILER OF A VAST RANGE OF ORGANICE CBD OILS AND COSMETICS

HIGHLIGHTS:

  • Current distributor of CBD products in Spain, Portugal, Austria, Germany, France and the United Kingdom
  • Number one search-ranked online retailer in Spain and Mexico
  • Award winning product line known for its minimal heavy metal content and accurate CBD levels
  • 100% organic products

 FIND OUT MORE!

Hub on Agoracom

FULL DISCLOSURE: Mota Ventures. is an advertising client of AGORA Internet Relations Corp.

Tags: , , , , , , , , , , , , ,
Posted in AGORACOM Client Feature, All Recent Posts, Mota Ventures Corp. | Comments Off on CLIENT FEATURE: Mota Ventures MOTA.ca – $29,000,000 in Combined Sales with 2019 EBITDA of Approximately 12.5% $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

CBD Market on Course to Grow 400% in Europe Alone SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:08 PM on Tuesday, March 10th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • Over the next five years, the global CBD market is expected to accelerate to $23.6bn, according to Grand View Research and Europe’s CBD market is set to grow by 400%.

The growth of the CBD market in Europe is thanks to the growing adoption of CBD infused products in industries such as pharmaceuticals, personal care, cosmetics, nutraceuticals, along with medical applications.

CBD is seeing monumental demand in Europe. In Europe alone, the market is on course to grow 400% over the next four years, according to the Brightfield Group.

According to New Frontier Data‘s EU CBD Consumer Report: 2019 Overview, 46% of Europeans view CBD favourably, and up to 77% of surveyed respondents also believe CBD should be accessible in some way.

CBD opportunities

The legal cannabis industry continues to expand around the world with major contribution to the market coming from continuous legislative victories in North America and Europe. In particular, legalisation of medical cannabis, and decriminalisation in some countries, has led to a significant decrease in black-market activity, as people are shifting to legally purchasing cannabis for medical as well as recreational use.

In the meantime, local governments reap the benefits through taxation. For instance, the state of California had collected a total of $345.2m in tax revenue from legal cannabis during the first year of regulated sales in 2018. Revenue generated from these taxes encouraged the local governments to fund several development programmes for education and infrastructure.

Medical cannabis

Overall, data by Grand View Research indicates that the medical segment held the dominant revenue share of the cannabis market, accounting for 71.0% in 2019. Medical use of cannabis is strictly categorised as a medicine prescribed by a physician and the distribution of these medicines is regulated by the government. However, by 2027, adult-use is expected to become the fastest-growing segment with adult-use products ranging from a highly potent concentrate to a simple food ingredient.

In recent years, CBD products have swiftly emerged and the growth of the CBD market is largely attributed to various medical applications that are associated with the products. For example, full-spectrum CBD oil is considered to be a great source of Omega 3 and Omega 6; Omega 3 plays a vital role in creating hormones that regulate inflammation as well as contractions and relaxation of arteries.

SOURCE: https://www.healtheuropa.eu/cbd-market-to-grow-400-in-europe/98021/

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on CBD Market on Course to Grow 400% in Europe Alone SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

First Look at the Nine CBD Consumer Archetypes in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:47 PM on Thursday, March 5th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Click Here for More Info

Mota large
  • New Frontier Data’s second consumer report in its EU CBD series provides a comprehensive overview of the European CBD consumer experience

New Frontier Data, the global authority in data, analytics and business intelligence on the cannabis industry, publishes the second volume of its EU CBD Consumer Report Series: Segmentation & Archetypes, in partnership with Deep Nature Project and Mile High Labs. Drawing from the groundbreaking surveying of over 3,000 European CBD consumers across 17 European nations, this study results in the most comprehensive consumer archetype report for European CBD consumers to date.

“Europe’s booming consumer interest in CBD and CBD-infused products across the Food & Beverage and Health & Beauty sectors continues to create material B2B and B2C market opportunities. Data-driven insights of both EU and North American CBD consumerism, drawing from not only comparative analysis but also known geo-centric market dynamics and drivers, helps us educate and guide brands on how to address CBD consumer priorities while managing known or expected challenges in this new CBD space,” said New Frontier Data Founder & CEO Giadha Aguirre de Carcer. “This report fills a major gap in business intelligence in the CBD industry not only in Europe, but worldwide, providing new and existing cannabis or hemp industry stakeholders with a uniquely valuable and timely resource.”

Key findings from the report include:

  • 4 of the 5 consumer archetypes have purchased CBD; the Ambivalent & Experimental Consumers instead source CBD from family and friends
  • The largest consumer archetype, the Integrative & Consistent Consumers, are frequent users and staunch believers in CBD’s medical efficacy
  • 26% of Europeans aged 18-34 have tried CBD, compared to 16% of the general population
  • 73% of self-reported consumers claimed CBD has positively affected their quality of life
  • A third (34%) of non-consumers are somewhat or very curious about trying CBD
  • 49% of CBD purchasers who did not themselves consume indicated buying it for a family member
  • Male consumers report spending more on CBD products than female consumers, with more than a third of men (35%) reporting spending €100 or more per month
  • 72% of consumers and 17% of non-consumers considered themselves likely to purchase CBD in the next 6 months
  • Consumers who use CBD primarily for medical reasons were the most frequent CBD consumers, with nearly half (45%) consuming it at least daily

The EU CBD Consumer Report Series: Segmentation & Archetypes is available for FREE Download at: https://newfrontierdata.com/product/the-eu-cbd-consumer-report-2020-segmentation-and-archetypes/

About New Frontier Data:

New Frontier Data is an independent, technology-driven analytics company specializing in the global cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators, researchers and policy makers. New Frontier Data’s reports and data have been cited in over 80 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C., with additional offices in Denver, CO and London, UK.

New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate are to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry worldwide. For more information about New Frontier Data, please visit: https://www.NewFrontierData.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005341/en/

Tags: , , , , , , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on First Look at the Nine CBD Consumer Archetypes in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

REPEAT: Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 9:10 AM on Thursday, February 27th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]

Tags: , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on REPEAT: Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 6:10 PM on Wednesday, February 26th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]

Tags: , , , , , , , ,
Posted in All Recent Posts, Mota Ventures Corp. | Comments Off on Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Newer Entries »